Chang XF, Ren XL, Yang JQ, et al. - Via this systematic review and meta-analysis, researchers evaluated the efficacy as well as safety of poly-ADP-ribose polymerase (PARP) inhibitors in breast cancer patients vs chemotherapy. For this purpose, they explored PubMed, EMBASE, CENTRAL, conference meetings and clinical trial registry. They analyzed six randomized controlled trials with 1,953 patients. According to findings, PARP inhibitors demonstrated significantly improved efficacy in progression-free survival and overall response rate. However, an increased risk of grade 3–4 thrombocytopenia was observed in relation to PARP inhibitors vs chemotherapy. To treat patients who had not received previous platinum treatment, a better option was PARP inhibitors.